Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase
Hepatic encephalopathy (HE) is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure. We studied the etiology of cerebral dysfunction in a murine model of HE induced by either bile duct ligation or thioacetamide administration. We report that stimulation of cer...
Gespeichert in:
Veröffentlicht in: | The FASEB journal 2007-08, Vol.21 (10), p.2431-2441 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2441 |
---|---|
container_issue | 10 |
container_start_page | 2431 |
container_title | The FASEB journal |
container_volume | 21 |
creator | Dagon, Yossi Avraham, Yosefa Ilan, Yaron Mechoulam, Raphael Berry, Elliot M |
description | Hepatic encephalopathy (HE) is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure. We studied the etiology of cerebral dysfunction in a murine model of HE induced by either bile duct ligation or thioacetamide administration. We report that stimulation of cerebral AMP-activated protein kinase (AMPK), a major intracellular energy sensor, is a compensatory response to liver failure. This function of AMPK is regulated by endocannabinoids. The cannabinoid system controls systemic energy balance via the cannabinoid receptors CB-1 and CB-2. Under normal circumstances, AMPK activity is mediated by CB-1 while CB-2 is barely detected. However, CB-2 is strongly stimulated in response to liver failure. Administration of Δ9-tetrahydrocannabinol (THC) augmented AMPK activity and restored brain function in WT mice but not in their CB-2 KO littermates. These results suggest that HE is a disease of energy flux. CB-2 signaling is a cerebral stress response mechanism and makes AMPK a promising target for its treatment by modulating the cannabinoid system.--Dagon, Y., Avraham, Y., Ilan, Y., Mechoulam, R., Berry, E. M. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. |
doi_str_mv | 10.1096/fj.06-7705com |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68106819</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20494727</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429M-bd0c3c6cdba853cef2061904b08817adff279ab4ee68f1f8b137ef99d97d87fe3</originalsourceid><addsrcrecordid>eNqFkctrGzEQh0VpaNykx15bnXrbdLQPPXpLTN0HMQkkOQutNApytatU8jr4v-8GG3prD8Mw8H2_gRlC3jO4YKD4Z7-5AF4JAZ1NwyuyYF0DFZccXpMFSFVXnDfylLwtZQMADBh_Q06ZaJvZ7hYEl2YcTR_GFFyhZsAYUjZbpBYz9tlE6vbFT6PdhjRSn2JMz2F8pDHsMFNvQpwy0l0w9HJ9W5kZ2822o085bTGM9FcYTcFzcuJNLPju2M_Iw-rr_fJ7dX3z7cfy8rqyba3WVe_ANpZb1xvZNRZ9DZwpaHuQkgnjvK-FMn2LyKVnXvasEeiVcko4KTw2Z-TTIXde_3vCstVDKBZjNCOmqWguGcyl_gvW0KpW1GIGqwNocyolo9dPOQwm7zUD_fIA7TcauD4-YOY_HIOnfkD3lz5efAa-HIDnEHH_7zS9uruqVz-Bv8zLm_UsfzzI3iRtHnMo-uGuBtYACNWB6Jo_9c6fkA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20494727</pqid></control><display><type>article</type><title>Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Dagon, Yossi ; Avraham, Yosefa ; Ilan, Yaron ; Mechoulam, Raphael ; Berry, Elliot M</creator><creatorcontrib>Dagon, Yossi ; Avraham, Yosefa ; Ilan, Yaron ; Mechoulam, Raphael ; Berry, Elliot M</creatorcontrib><description>Hepatic encephalopathy (HE) is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure. We studied the etiology of cerebral dysfunction in a murine model of HE induced by either bile duct ligation or thioacetamide administration. We report that stimulation of cerebral AMP-activated protein kinase (AMPK), a major intracellular energy sensor, is a compensatory response to liver failure. This function of AMPK is regulated by endocannabinoids. The cannabinoid system controls systemic energy balance via the cannabinoid receptors CB-1 and CB-2. Under normal circumstances, AMPK activity is mediated by CB-1 while CB-2 is barely detected. However, CB-2 is strongly stimulated in response to liver failure. Administration of Δ9-tetrahydrocannabinol (THC) augmented AMPK activity and restored brain function in WT mice but not in their CB-2 KO littermates. These results suggest that HE is a disease of energy flux. CB-2 signaling is a cerebral stress response mechanism and makes AMPK a promising target for its treatment by modulating the cannabinoid system.--Dagon, Y., Avraham, Y., Ilan, Y., Mechoulam, R., Berry, E. M. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase.</description><identifier>ISSN: 0892-6638</identifier><identifier>EISSN: 1530-6860</identifier><identifier>DOI: 10.1096/fj.06-7705com</identifier><identifier>PMID: 17431095</identifier><language>eng</language><publisher>United States: The Federation of American Societies for Experimental Biology</publisher><subject>AMP-Activated Protein Kinases ; AMPK ; Animals ; Bile Ducts - physiology ; Brain - drug effects ; Brain - physiopathology ; Cannabinoids - therapeutic use ; Dronabinol - therapeutic use ; endocannabinoid receptor ; Female ; hepatic encephalopathy ; Hepatic Encephalopathy - prevention & control ; liver disease ; Liver Failure - complications ; Mice ; Mice, Inbred Strains ; Multienzyme Complexes - metabolism ; Protein-Serine-Threonine Kinases - metabolism</subject><ispartof>The FASEB journal, 2007-08, Vol.21 (10), p.2431-2441</ispartof><rights>FASEB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429M-bd0c3c6cdba853cef2061904b08817adff279ab4ee68f1f8b137ef99d97d87fe3</citedby><cites>FETCH-LOGICAL-c429M-bd0c3c6cdba853cef2061904b08817adff279ab4ee68f1f8b137ef99d97d87fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1096%2Ffj.06-7705com$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1096%2Ffj.06-7705com$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17431095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dagon, Yossi</creatorcontrib><creatorcontrib>Avraham, Yosefa</creatorcontrib><creatorcontrib>Ilan, Yaron</creatorcontrib><creatorcontrib>Mechoulam, Raphael</creatorcontrib><creatorcontrib>Berry, Elliot M</creatorcontrib><title>Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase</title><title>The FASEB journal</title><addtitle>FASEB J</addtitle><description>Hepatic encephalopathy (HE) is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure. We studied the etiology of cerebral dysfunction in a murine model of HE induced by either bile duct ligation or thioacetamide administration. We report that stimulation of cerebral AMP-activated protein kinase (AMPK), a major intracellular energy sensor, is a compensatory response to liver failure. This function of AMPK is regulated by endocannabinoids. The cannabinoid system controls systemic energy balance via the cannabinoid receptors CB-1 and CB-2. Under normal circumstances, AMPK activity is mediated by CB-1 while CB-2 is barely detected. However, CB-2 is strongly stimulated in response to liver failure. Administration of Δ9-tetrahydrocannabinol (THC) augmented AMPK activity and restored brain function in WT mice but not in their CB-2 KO littermates. These results suggest that HE is a disease of energy flux. CB-2 signaling is a cerebral stress response mechanism and makes AMPK a promising target for its treatment by modulating the cannabinoid system.--Dagon, Y., Avraham, Y., Ilan, Y., Mechoulam, R., Berry, E. M. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase.</description><subject>AMP-Activated Protein Kinases</subject><subject>AMPK</subject><subject>Animals</subject><subject>Bile Ducts - physiology</subject><subject>Brain - drug effects</subject><subject>Brain - physiopathology</subject><subject>Cannabinoids - therapeutic use</subject><subject>Dronabinol - therapeutic use</subject><subject>endocannabinoid receptor</subject><subject>Female</subject><subject>hepatic encephalopathy</subject><subject>Hepatic Encephalopathy - prevention & control</subject><subject>liver disease</subject><subject>Liver Failure - complications</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Multienzyme Complexes - metabolism</subject><subject>Protein-Serine-Threonine Kinases - metabolism</subject><issn>0892-6638</issn><issn>1530-6860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctrGzEQh0VpaNykx15bnXrbdLQPPXpLTN0HMQkkOQutNApytatU8jr4v-8GG3prD8Mw8H2_gRlC3jO4YKD4Z7-5AF4JAZ1NwyuyYF0DFZccXpMFSFVXnDfylLwtZQMADBh_Q06ZaJvZ7hYEl2YcTR_GFFyhZsAYUjZbpBYz9tlE6vbFT6PdhjRSn2JMz2F8pDHsMFNvQpwy0l0w9HJ9W5kZ2822o085bTGM9FcYTcFzcuJNLPju2M_Iw-rr_fJ7dX3z7cfy8rqyba3WVe_ANpZb1xvZNRZ9DZwpaHuQkgnjvK-FMn2LyKVnXvasEeiVcko4KTw2Z-TTIXde_3vCstVDKBZjNCOmqWguGcyl_gvW0KpW1GIGqwNocyolo9dPOQwm7zUD_fIA7TcauD4-YOY_HIOnfkD3lz5efAa-HIDnEHH_7zS9uruqVz-Bv8zLm_UsfzzI3iRtHnMo-uGuBtYACNWB6Jo_9c6fkA</recordid><startdate>200708</startdate><enddate>200708</enddate><creator>Dagon, Yossi</creator><creator>Avraham, Yosefa</creator><creator>Ilan, Yaron</creator><creator>Mechoulam, Raphael</creator><creator>Berry, Elliot M</creator><general>The Federation of American Societies for Experimental Biology</general><general>Federation of American Societies for Experimental Biology</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>200708</creationdate><title>Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase</title><author>Dagon, Yossi ; Avraham, Yosefa ; Ilan, Yaron ; Mechoulam, Raphael ; Berry, Elliot M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429M-bd0c3c6cdba853cef2061904b08817adff279ab4ee68f1f8b137ef99d97d87fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>AMP-Activated Protein Kinases</topic><topic>AMPK</topic><topic>Animals</topic><topic>Bile Ducts - physiology</topic><topic>Brain - drug effects</topic><topic>Brain - physiopathology</topic><topic>Cannabinoids - therapeutic use</topic><topic>Dronabinol - therapeutic use</topic><topic>endocannabinoid receptor</topic><topic>Female</topic><topic>hepatic encephalopathy</topic><topic>Hepatic Encephalopathy - prevention & control</topic><topic>liver disease</topic><topic>Liver Failure - complications</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Multienzyme Complexes - metabolism</topic><topic>Protein-Serine-Threonine Kinases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dagon, Yossi</creatorcontrib><creatorcontrib>Avraham, Yosefa</creatorcontrib><creatorcontrib>Ilan, Yaron</creatorcontrib><creatorcontrib>Mechoulam, Raphael</creatorcontrib><creatorcontrib>Berry, Elliot M</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dagon, Yossi</au><au>Avraham, Yosefa</au><au>Ilan, Yaron</au><au>Mechoulam, Raphael</au><au>Berry, Elliot M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase</atitle><jtitle>The FASEB journal</jtitle><addtitle>FASEB J</addtitle><date>2007-08</date><risdate>2007</risdate><volume>21</volume><issue>10</issue><spage>2431</spage><epage>2441</epage><pages>2431-2441</pages><issn>0892-6638</issn><eissn>1530-6860</eissn><abstract>Hepatic encephalopathy (HE) is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure. We studied the etiology of cerebral dysfunction in a murine model of HE induced by either bile duct ligation or thioacetamide administration. We report that stimulation of cerebral AMP-activated protein kinase (AMPK), a major intracellular energy sensor, is a compensatory response to liver failure. This function of AMPK is regulated by endocannabinoids. The cannabinoid system controls systemic energy balance via the cannabinoid receptors CB-1 and CB-2. Under normal circumstances, AMPK activity is mediated by CB-1 while CB-2 is barely detected. However, CB-2 is strongly stimulated in response to liver failure. Administration of Δ9-tetrahydrocannabinol (THC) augmented AMPK activity and restored brain function in WT mice but not in their CB-2 KO littermates. These results suggest that HE is a disease of energy flux. CB-2 signaling is a cerebral stress response mechanism and makes AMPK a promising target for its treatment by modulating the cannabinoid system.--Dagon, Y., Avraham, Y., Ilan, Y., Mechoulam, R., Berry, E. M. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase.</abstract><cop>United States</cop><pub>The Federation of American Societies for Experimental Biology</pub><pmid>17431095</pmid><doi>10.1096/fj.06-7705com</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0892-6638 |
ispartof | The FASEB journal, 2007-08, Vol.21 (10), p.2431-2441 |
issn | 0892-6638 1530-6860 |
language | eng |
recordid | cdi_proquest_miscellaneous_68106819 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
subjects | AMP-Activated Protein Kinases AMPK Animals Bile Ducts - physiology Brain - drug effects Brain - physiopathology Cannabinoids - therapeutic use Dronabinol - therapeutic use endocannabinoid receptor Female hepatic encephalopathy Hepatic Encephalopathy - prevention & control liver disease Liver Failure - complications Mice Mice, Inbred Strains Multienzyme Complexes - metabolism Protein-Serine-Threonine Kinases - metabolism |
title | Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T07%3A28%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cannabinoids%20ameliorate%20cerebral%20dysfunction%20following%20liver%20failure%20via%20AMP-activated%20protein%20kinase&rft.jtitle=The%20FASEB%20journal&rft.au=Dagon,%20Yossi&rft.date=2007-08&rft.volume=21&rft.issue=10&rft.spage=2431&rft.epage=2441&rft.pages=2431-2441&rft.issn=0892-6638&rft.eissn=1530-6860&rft_id=info:doi/10.1096/fj.06-7705com&rft_dat=%3Cproquest_cross%3E20494727%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20494727&rft_id=info:pmid/17431095&rfr_iscdi=true |